FDA Orange Book · active-ingredient family
Dinoprostone
Dinoprostone is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:CERVIDIL · NDA 020411
3
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · gel, insert, extended release, suppository
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CERVIDILRLD | FERRING PHARMS INC | NDA 020411 | — | Mar 30, 1995 | |
| PREPIDILRLD | PFIZER | NDA 019617 | — | Dec 09, 1992 | |
| PROSTIN E2RLD | PFIZER | NDA 017810 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Dinoprostone — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

